Can Probiotics Supplementation Improve Glycemic & Renal Status in Diabetic Nephropathy? A Systematic Review and Meta-Analysis of Clinical Trials

(E-pub Ahead of Print)

Author(s): Mohammad Javad Tarrahi, Iman Namjoo, Mohammad Borzoo-Isfahani, Hadiseh Ebdali, Amir Reza Moravejolahkami*

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Become EABM
Become Reviewer
Call for Editor


Background & Aims: This meta-analysis was performed to quantify the effects of probiotics on renal and glycemic biomarkers among patients with Diabetic Nephropathy (DN).

Methods: Electronic databases were searched through May 10, 2020. All trials that investigated the effect of probiotics on serum glycemic markers (Fasting Plasma Glucose [FPG], Hemoglobin A1C, Insulin, Homeostatic Model AssessmentInsulin Resistance [HOMA-IR], and Quantitative Insulin Sensitivity Check Index [QUICKI]), and renal status markers (Creatinine [Cr], Blood Urea Nitrogen [BUN], and Glomerular Filtration Rate [GFR]) were included.

Results: Seven trials that included 340 patients were identified for analysis. The results indicated that probiotics significantly reduced FPG (WMD= -19.08 mg/dl; 95% CI= -32.16, -5.99; P=0.004), HOMA-IR (WMD= -1.88; 95% CI= - 3.63, -0.12; P=0.036), and Cr (WMD= -0.18 mg/dl; 95% CI= -0.26, -0.09; P<0.001) levels in DN patients; however, there was no statistically significant change in Hemoglobin A1C, Insulin, QUICKI, BUN, and GFR.

Conclusion: This meta-analysis supports the potential use of probiotics in the improvement of some glycemic and renal biomarkers in patients with DN.

Keywords: Probiotics, clinical laboratory techniques, diabetic nephropathies, meta-analysis, systematic review.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 21 January, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1871530321666210121154037
Price: $95

Article Metrics

PDF: 193